Stocks-BPMC-Blueprint Medicines Corp

BPMC Blueprint Medicines Corp

50.22 -0.85 (-1.66%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Stocks-BPMC-Blueprint Medicines Corp
BPMC Blueprint Medicines Corp
Trade

Blueprint Medicines Corp price

0% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
3.05B
Day’s Range
49.79
-
51.80
52W Range
37.69
-
68.42
Volume (3M)
613.57K
Price-Earnings Ratio
-5.44
Revenue
225.62M

Blueprint Medicines Corp Latest News

View All
Director Jeffrey Albers Sells —5,……… Shares of Blueprint Medicines CorpDirector Jeffrey Albers Sells —5,……… Shares of Blueprint Medicines CorpGuruFocusabout 10 hours ago
Top Discussions

About Blueprint Medicines Corp

Blueprint Medicines Corp is an American pharmaceutical and medical manufacturing company based in Cambridge, Massachusetts. Established in 2008, the firm focuses on the identification of kinases that act as drivers of genomically defined cancers and hematologic disorders. Operating globally, the firm uses its research to develop precision therapies that aim to provide significant clinical responses in patients and greatly increase quality of life. The firm’s products include AYVAKIT/AYVAKYT (avapritinib), which is used for the treatment of a rare hematologic disorder called systemic mastocytosis (SM), characterised by the production of excess mast cells leading to the accumulation of mast cells in the bone marrow and other organs. Blueprint also produces GAVRETO (pralsetinib), an oral therapy for patients with RET-positive metastatic non-small lung cancer and advanced thyroid cancer. The company has a number of products in the pipeline at various clinical and pre-clinical phases, primarily focused on improving outcomes for patients living with genomically defined cancers, advanced cancers, and hematologic disorders. The firm worked in collaboration with Genentech, a member of the Roche Group, to develop and commercialise pralsetinib as a therapy for patients with RET-altered cancers. Blueprint Medicines Corp is listed on the NASDAQ, where it trades under the stock ticker BPMC. Learn more about the performance of BPMC share prices on eToro.
Kathryn Haviland, MBA
CEO
641
Employees
2008
Founded
Cambridge, Massachusetts, US
HQ
Show More
Med TechNASDAQ

Upcoming Events

31
OCT
REPORTS
Blueprint Medicines Corp Q3 2023 earnings report is expected to be released before market open

Analyst Forecast

Consensus
Strong Buy
Price Target
82.33
Based on 3 analysts who covered BPMC 

ESG: A New Source of Insight

What is an ESG Score?
This number is a measure of a company’s exposure to environmental, social, and governance risks. Influencing factors include energy efficiency, safety, social policies, and more. Learn More
Powered by ESG Book
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
49
Medium
Industry 
Avg. 45 
37
Environment
44
Social
59
Governance

People Also Bought